Weight and BMI Patterns in Biological Based IBD Patients and Its Finacial Impact
Observational · No treatment assigned · Sites not listed yet · Assiut University
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Inflammatory Bowel Diseases Weight Changes. This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 18 to 60
- Any sex
- Healthy volunteers accepted
Some of the main requirements, copied from the record:
- Patients must have received infliximab (IFX) therapy for at least 14 weeks and completed the on-label induction regimen (5 mg/kg IV at weeks 0, 2, and 6), regardless of the dose at the time of blood collection (patients receiving optimized…
- Patients may be on IFX monotherapy or in combination with one of the following medications at the time of selection: aminosalicylates, antibiotics, prednisone, azathioprine, 6-mercaptopurine, or methotrexate.
There are also 2 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 50 participants are expected to take part.
- Start date: 2026-05-01 (planned).
- Main results expected around 2026-12-01 (estimate from the record).
- No study sites are listed yet. Check the official record for contact details.
Main thing being measured
- Pattern of Weight Changes in Biologic-Treated IBD Patients (Monthly assessment for 12 month)
In the researchers’ words
Primary Objective To determine the pattern of weight and body mass index (BMI) changes in biologic-treated patients with inflammatory bowel disease (IBD). Secondary Objectives To evaluate the correlation between BMI and biologic drug dosing.
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Not yet recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Inflammatory Bowel Diseases Weight Changes |
| Lead sponsor | Assiut University |
| Enrollment | 50 (estimated) |
| Start date | 2026-05-01 |
| Primary completion (est.) | 2026-12-01 |
| First posted | 2026-03-27 |
| Last updated | 2026-03-30 |
| Official title | Weight and BMI Patterns in Biological Based IBD Patients and Its Finacial Impact |
| ClinicalTrials.gov ID | NCT07495800 |
Interventions
- None listed
Full eligibility criteria (from the record)
Inclusion Criteria: * Patients must have received infliximab (IFX) therapy for at least 14 weeks and completed the on-label induction regimen (5 mg/kg IV at weeks 0, 2, and 6), regardless of the dose at the time of blood collection (patients receiving optimized doses are eligible). * Patients may be on IFX monotherapy or in combination with one of the following medications at the time of selection: aminosalicylates, antibiotics, prednisone, azathioprine, 6-mercaptopurine, or methotrexate. Exclusion Criteria: * Patients receiving IFX in combination with tacrolimus, cyclosporine, sirolimus, mycophenolate mofetil, another immunobiological agent, or tofacitinib. * Patients with insufficient data in their electronic medical records.
Locations (0)
No sites listed yet. The official record has contact information.
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.